Skip to content

Pain Perception During Vulvar Biopsy

A Comparison of Pain Perception Using Topical EMLA Cream Versus Lidocaine Injection for Vulvar Biopsy: a Randomized Controlled Trial

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03654417
Enrollment
37
Registered
2018-08-31
Start date
2018-09-17
Completion date
2019-03-12
Last updated
2020-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any Condition Requiring Vulvar Biopsy

Keywords

vulvar biopsy

Brief summary

The purpose of this study is to compare pain control during vulvar biopsy following either (1) application of EMLA (a eutectic mixture of local anesthetics lidocaine 2.5% and prilocaine 2.5%) cream or (2) injection of 1% lidocaine. We hypothesize that lidocaine will provide better biopsy analgesia, but the benefit will be offset by the pain of lidocaine injection compared to EMLA application, thus there will not be a significant difference in highest pain scores between the two groups.

Detailed description

Performing minor procedures in-office is essential to gynecologic practices. In-office procedures allow for evaluation and diagnosis of a variety of conditions while avoiding the expense, anesthesia, and time associated with the operating room. Pain and discomfort are frequently associated with these procedures, and ensuring that the patient has the least amount of discomfort is a priority. Very painful or uncomfortable procedures could potentially discourage a patient from returning to clinic or receiving the follow up that they may need. Psychological, physiologic, and social factors influence a patient's experience of pain. Previous studies, though mostly related to first trimester abortion procedures in the office, indicate that the procedure type, anxiety, depression, and general anticipation of pain predict increased pain during in office gynecologic procedures (1-4). A review by Ireland et al., found that a multimodal approach that includes patient counseling with other techniques is most effective in achieving optimum pain control for procedures (5,6). Vulvar biopsies are associated with significant discomfort, and some form of anesthesia is required. The current standard in our group is to inject local anesthesia prior to vulvar biopsy. However, the injection itself is associated with its own level of pain that is not insignificant, and for many, the anticipation of receiving an injection is anxiety provoking. The use of topical anesthesia in lieu of injection or as pre-injection analgesia is variable. Several previous studies have examined the use of topical anesthetics in the place of or in addition to injected anesthesia. Drouault et al. compared EMLA cream alone to injected lidocaine alone for pain relief in vulvar biopsy and found that pain associated with administration of anesthesia was significantly less for EMLA cream, but better biopsy analgesia was obtained with injected anesthesia. The study considered combined pain scores for both groups for the overall procedure (anesthesia + biopsy), it comments that the combined scores were lower for the EMLA group but failed to reach statistical significance. The study ultimately concluded that EMLA is the less painful procedure to obtain anesthesia and that it can be used as an alternative to injection for biopsies of the genital mucosa (7). This prior study did not compare the highest pain score between groups. Consideration of the highest pain score allows us to assess whether the injection of lidocaine could result in causing more pain than the biopsy itself using EMLA cream alone for anesthesia. Further, the study did not assess the subjects' or the providers' perception of the tolerability and acceptability of performing the procedure using either method. This is an important factor in any in office procedure EMLA cream is the most extensively studied topical anesthetic. It is FDA approved for use as a topical anesthetic on the genital mucous membranes for superficial, minor surgery. EMLA cream requires between 7-10 minutes of absorption time on the genital mucosa for analgesic effect, with variable duration of analgesia following, usually around 15-20 minutes (9). There is a highly variable absorption rate for EMLA cream depending on the characteristics of the epithelium upon which it is applied as well as the duration and surface area of cream applied. On hair-bearing non-mucosal surfaces it can require 60 minutes of application time to obtain analgesic affect (10). The vulvar area is unique in that it contains both mucosal and non-mucosal and hair-bearing surfaces; this could greatly affect the absorption of EMLA and therefore affect analgesia. For this reason, we will exclude from the study patients requiring vulvar biopsy on hair bearing portion of the vulva. Several previous studies have examined the use of topical anesthetics in the place of or in addition to injected anesthesia. Drouault et al. compared EMLA cream to injected lidocaine as described above. The study found that pain associated with administration of anesthesia was significantly less for EMLA cream, but better biopsy analgesia was obtained with injected anesthesia. However, there were some limitations to this study also noted above, that we plan to expand and improve upon with the current study. Zilbert and Lewandoswki studied pre-treatment with EMLA cream prior to anesthesia injection and found that pain was decreased by 50% in patients pretreated compared to placebo prior to lidocaine injection. Van den Berg studied application of EMLA alone versus lidocaine injection alone in punch biopsies and electrocoagulation of genital warts in men. The study found that in the punch biopsy cohort that the total pain scores (application of EMLA + biopsy versus injection of lidocaine + biopsy) were less for the EMLA group than the injected lidocaine group and the difference was statistically significant (11). With its FDA approval for use as a topical anesthetic on the genital mucous membranes for superficial, minor surgery, it can be considered a standard of care to use EMLA for anesthesia prior to biopsy as an alternative to injection of lidocaine (10) As there are no studies that consider the subjects' or the providers' perception of the acceptability or the tolerability of the procedure, this will be novel data for vulvar biopsy. However, acceptability and tolerability have been assessed in other procedural settings, such as in office endoscopic procedures, in which BS-11, a validated 11 point scale, is used to assess pain, anxiety, acceptability, tolerability, and levels of other procedure related symptoms (12-13).

Interventions

DRUGEMLA

Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.

DRUGLidocaine

Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 89 Years
Healthy volunteers
No

Inclusion criteria

* Females above age 18 presenting to Duke Gynecology Oncology clinic for vulvar biopsy * Able to provide informed consent in English and agree to the risks of the study

Exclusion criteria

* Not able to provide informed consent * Vulvar biopsy on a hair bearing surface

Design outcomes

Primary

MeasureTime frameDescription
Highest Pain Scoreno more than 5 minutes after numbing or 5 minutes after biopsyThe highest pain score recorded (at time of numbing or at time of biopsy) controlled for baseline pain title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during numbing OR biopsy min: 0 (no pain) max: 100 (worst pain imaginable)

Secondary

MeasureTime frameDescription
Baseline Vulvar Painno more than 30 minutes prior to procedureself-reported level of vulvar pain immediately prior to the start of the procedure title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during biopsy min: 0 (no pain) max: 100 (worst pain imaginable)
Anxiety Before the Procedure as Measured by an Anxiety ScaleNo more than 30 minutes before the procedureself-reported level of anxiety immediately prior to the start of the procedure title: Slide the tab along the line below to indicate how nervous you feel about the procedure you are about to have min: 0 (not nervous) max: 100 (very nervous)
Generalized Anxiety Disorder 7-item (GAD-7) Score for Baseline Anxietyno more than 30 minutes before the procedureSelf-reported anxiety score meant to assess a patient's baseline level of anxiety. The score ranges from 0 (minimal anxiety) to 21 (severe anxiety).
Pain During Biopsy as Measured by a Pain ScaleNo more than 5 minutes after receiving the biopsyself-reported level of pain following the biopsy title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during biopsy min: 0 (no pain) max: 100 (worst pain imaginable)
Tolerance of Procedure as Measured by a Satisfaction ScaleUp to 30 minutes after the procedureself-reported tolerance of the procedure meant to assess a patient's tolerance through a scale Title: Please slide the tab along the line below to indicate, overall, how you would rate the experience of your biopsy procedure today Min: 0 (I could easily handle having this procedure again) Max: 100 (I could never have this procedure done again)
Provider's Opinion of Subject Tolerance as Measured by a ScaleUp to 30 minutes after the procedureprovider-reported measure of how well they believe the patient tolerated the procedure title: Overall, how well did the subject tolerate the procedure today? min: 0 (well tolerated) max: 100 (poorly tolerated)
Provider's Overall Satisfaction With the Procedure as Measured by a ScaleUp to 30 minutes after the procedureprovider-reported measure of how well they believe the procedure went title: Overall, how satisfied are you with the procedure performed today? min: 0 (completely satisfied) max: 100 (not at all satisfied)
Acceptance of the Procedure as Measured by a Satisfaction Scaleup to 30 minutes after the procedureself-reported acceptance of the procedure meant to assess a patient's acceptability through a scale title: Please slide the tab along the line below to indicate, overall, how acceptable the procedure performed today was min: 0 (completely acceptable) max: 100 (not at all acceptable)

Countries

United States

Participant flow

Participants by arm

ArmCount
EMLA
Lidocaine: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
19
Lidocaine
EMLA: Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
18
Total37

Baseline characteristics

CharacteristicLidocaineTotalEMLA
Age, Continuous58.5 years60 years60 years
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
18 Participants36 Participants18 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
9 Participants16 Participants7 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
9 Participants21 Participants12 Participants
Sex: Female, Male
Female
18 Participants37 Participants19 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 190 / 18
other
Total, other adverse events
0 / 190 / 18
serious
Total, serious adverse events
0 / 190 / 18

Outcome results

Primary

Highest Pain Score

The highest pain score recorded (at time of numbing or at time of biopsy) controlled for baseline pain title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during numbing OR biopsy min: 0 (no pain) max: 100 (worst pain imaginable)

Time frame: no more than 5 minutes after numbing or 5 minutes after biopsy

ArmMeasureValue (MEDIAN)
EMLAHighest Pain Score20 units on a scale (mm)
LidocaineHighest Pain Score56.5 units on a scale (mm)
Secondary

Acceptance of the Procedure as Measured by a Satisfaction Scale

self-reported acceptance of the procedure meant to assess a patient's acceptability through a scale title: Please slide the tab along the line below to indicate, overall, how acceptable the procedure performed today was min: 0 (completely acceptable) max: 100 (not at all acceptable)

Time frame: up to 30 minutes after the procedure

ArmMeasureValue (MEDIAN)
EMLAAcceptance of the Procedure as Measured by a Satisfaction Scale0 units on a scale (mm)
LidocaineAcceptance of the Procedure as Measured by a Satisfaction Scale10.5 units on a scale (mm)
Secondary

Anxiety Before the Procedure as Measured by an Anxiety Scale

self-reported level of anxiety immediately prior to the start of the procedure title: Slide the tab along the line below to indicate how nervous you feel about the procedure you are about to have min: 0 (not nervous) max: 100 (very nervous)

Time frame: No more than 30 minutes before the procedure

ArmMeasureValue (MEDIAN)
EMLAAnxiety Before the Procedure as Measured by an Anxiety Scale19 units on a scale (mm)
LidocaineAnxiety Before the Procedure as Measured by an Anxiety Scale31.5 units on a scale (mm)
Secondary

Baseline Vulvar Pain

self-reported level of vulvar pain immediately prior to the start of the procedure title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during biopsy min: 0 (no pain) max: 100 (worst pain imaginable)

Time frame: no more than 30 minutes prior to procedure

ArmMeasureValue (MEDIAN)
EMLABaseline Vulvar Pain0.0 units on a scale (mm)
LidocaineBaseline Vulvar Pain0.0 units on a scale (mm)
Secondary

Generalized Anxiety Disorder 7-item (GAD-7) Score for Baseline Anxiety

Self-reported anxiety score meant to assess a patient's baseline level of anxiety. The score ranges from 0 (minimal anxiety) to 21 (severe anxiety).

Time frame: no more than 30 minutes before the procedure

ArmMeasureCategoryValue (COUNT_OF_PARTICIPANTS)
EMLAGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyModerate Anxiety (10-14)0 Participants
EMLAGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietySevere Anxiety (15-21)1 Participants
EMLAGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyMinimal Anxiety (0-4)13 Participants
EMLAGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyMild Anxiety (5-9)5 Participants
LidocaineGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyMild Anxiety (5-9)5 Participants
LidocaineGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyModerate Anxiety (10-14)1 Participants
LidocaineGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietyMinimal Anxiety (0-4)11 Participants
LidocaineGeneralized Anxiety Disorder 7-item (GAD-7) Score for Baseline AnxietySevere Anxiety (15-21)1 Participants
Secondary

Pain During Biopsy as Measured by a Pain Scale

self-reported level of pain following the biopsy title: Please slide the tab along the line below to indicate pain in the area of your vulva (external genitalia) during biopsy min: 0 (no pain) max: 100 (worst pain imaginable)

Time frame: No more than 5 minutes after receiving the biopsy

ArmMeasureValue (MEDIAN)
EMLAPain During Biopsy as Measured by a Pain Scale6 units on a scale (mm)
LidocainePain During Biopsy as Measured by a Pain Scale3 units on a scale (mm)
Secondary

Provider's Opinion of Subject Tolerance as Measured by a Scale

provider-reported measure of how well they believe the patient tolerated the procedure title: Overall, how well did the subject tolerate the procedure today? min: 0 (well tolerated) max: 100 (poorly tolerated)

Time frame: Up to 30 minutes after the procedure

ArmMeasureValue (MEDIAN)
EMLAProvider's Opinion of Subject Tolerance as Measured by a Scale3 units on a scale (mm)
LidocaineProvider's Opinion of Subject Tolerance as Measured by a Scale15 units on a scale (mm)
Secondary

Provider's Overall Satisfaction With the Procedure as Measured by a Scale

provider-reported measure of how well they believe the procedure went title: Overall, how satisfied are you with the procedure performed today? min: 0 (completely satisfied) max: 100 (not at all satisfied)

Time frame: Up to 30 minutes after the procedure

ArmMeasureValue (MEDIAN)
EMLAProvider's Overall Satisfaction With the Procedure as Measured by a Scale3 units on a scale (mm)
LidocaineProvider's Overall Satisfaction With the Procedure as Measured by a Scale9.5 units on a scale (mm)
Secondary

Tolerance of Procedure as Measured by a Satisfaction Scale

self-reported tolerance of the procedure meant to assess a patient's tolerance through a scale Title: Please slide the tab along the line below to indicate, overall, how you would rate the experience of your biopsy procedure today Min: 0 (I could easily handle having this procedure again) Max: 100 (I could never have this procedure done again)

Time frame: Up to 30 minutes after the procedure

ArmMeasureValue (MEDIAN)
EMLATolerance of Procedure as Measured by a Satisfaction Scale2 units on a scale (mm)
LidocaineTolerance of Procedure as Measured by a Satisfaction Scale17 units on a scale (mm)
Post Hoc

Possible Pathologic Changes Associated With EMLA Cream Application

To address the concern that EMLA might induce pathologic changes that could result in altered diagnosis, pathologist independent from initial diagnostic read will re-evaluate tissue slides and look for the previously described EMLA induced pathologic changes (pallor, necrosis, spongiosis, basophilic granules, acantholysis, clefting, papillary dermal edema). Pathologist will be blinded to whether or not patient received EMLA cream for biopsy. They will provide a score for all specimens that will be used to analyse any pathologic differences between patients exposed to EMLA and those not exposed to EMLA.

Time frame: retrospective

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026